Zionsville, IN, United States of America

Sudhakar Reddy Chintharlapalli

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sudhakar Reddy Chintharlapalli: Innovator in Chemokine Antibodies

Introduction

Sudhakar Reddy Chintharlapalli is a notable inventor based in Zionsville, IN (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target specific chemokines. His work has implications for treating various inflammatory and autoimmune diseases, as well as certain types of cancer.

Latest Patents

Chintharlapalli holds a patent for Pan-ELR+ CXC chemokine antibodies. This invention provides antibodies that specifically bind to seven human ELR+ CXC chemokines. The antibodies are particularly useful in treating inflammatory bowel disease (IBD), plaque psoriasis, palmoplantar pustulosis, and cancers such as renal and ovarian cancer. He has 1 patent to his name.

Career Highlights

Chintharlapalli is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role involves research and development in the field of therapeutic antibodies, contributing to innovative solutions for complex health issues.

Collaborations

He has collaborated with notable colleagues, including Catherine Brautigam Beidler and Kristine Kay Kikly, who share a commitment to advancing medical science through innovative research.

Conclusion

Sudhakar Reddy Chintharlapalli's work in chemokine antibodies exemplifies the impact of innovation in biotechnology. His contributions are paving the way for new treatments for serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…